Table 6.
Study | Agents | Number of patients | RR | PFS median | OS median |
---|---|---|---|---|---|
OCEANS42 | GC + bev | 242 | 78.5% | 12.4 months; | 10.4 months |
HR 0.484 (0.388–0.605) | HR 0.534 | ||||
P < 0.0001 | (0.408–0.698) | ||||
GC + placebo | 242 | 57.4% | 8.4 months | 7.4 months |
Abbreviations: bev, bevacizumab; EOC, epithelial ovarian cancer; GC, gemcitabine and carboplatin; HR, hazard ratio; OCEANS, The Ovarian Cancer Education Awareness Network; OS, overall survival; PFS, progression-free survival; RR, relative risk.